Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 14/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.57 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8637392 | 0.91 | PTGS2 (0.68) | PTGESPTGS2PTGS1PDPK1HDAC3 | |
| SCHEMBL8639295 | 0.90 | PTGS2 (0.70) | PTGESPTGS2PTGS1PDPK1HDAC3 | |
| SCHEMBL8639809 | 0.88 | PTGS2 (0.55) | PTGESPTGS2PTGS1PDPK1HDAC3 | |
| SCHEMBL8644141 | 0.87 | PTGS2 (0.55) | PTGESPTGS2PTGS1PDPK1HDAC3 | |
| SCHEMBL6912425 | 0.85 | PTGS2 (0.66) | PTGESPTGS2PTGS1PDPK1HDAC3 | |
| SCHEMBL29502699 | 0.85 | PTGS2 (0.66) | PTGESPTGS2PTGS1PDPK1HDAC3 | |
| SCHEMBL8643953 | 0.84 | PTGS2 (0.56) | PTGESPTGS2PTGS1PDPK1 | |
| SCHEMBL8641602 | 0.83 | PTGS2 (0.53) | PTGESPTGS2PTGS1PDPK1HDAC3 | |
| SCHEMBL8638534 | 0.83 | PTGS2 (0.69) | PTGESPTGS2PTGS1PDPK1HDAC3 | |
| SCHEMBL8640004 | 0.83 | PTGS2 (0.55) | PTGESPTGS2PTGS1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034567-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies, Inc. (US) | 2022-08-03 | — | — | EP | claimed |
| US-11147809-B2 | Methods of treating neurofibromatosis with perillyl alcohol | Neonc Technologies, Inc. (US) | 2021-10-19 | — | — | US | claimed |
| US-9499461-B2 | Pharmaceutical compositions comprising POH derivatives | Neonc Technologies, Inc. (US) | 2016-11-22 | — | — | US | claimed |
| EP-2609064-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DERIVATIVES OF PERILLYL ALCOHOL | NEONC TECHNOLOGIES INC (US) | 2016-09-28 | — | — | EP | claimed |
| EP-2609064-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies Inc. (US) | 2013-07-03 | — | — | EP | claimed |
| WO-2012027693-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2012-03-01 | — | — | WO | claimed |
| EP-4656641-A2 | METHODS AND DEVICES FOR USING ISOPERILLYL ALCOHOL | University of Southern California (US) | 2025-12-03 | — | — | EP | disclosed |
| CN-117715636-A | Pharmaceutical composition comprising POH derivatives | 南加利福尼亚大学 | 2024-03-15 | — | — | CN | disclosed |
| EP-4323070-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20240016800-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2024-01-18 | — | — | US | disclosed |
| US-11786521-B2 | Methods of treating neurofibromatosis with perillyl alcohol | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2022221759-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies, Inc. (US) | 2022-10-20 | — | — | WO | disclosed |
| EP-4034567-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| US-11147809-B2 | Methods of treating neurofibromatosis with perillyl alcohol | Neonc Technologies, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3612185-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES AND METHODS OF USE | Neonc Technologies, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190167669-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2019-06-06 | — | — | US | disclosed |
| WO-2019014420-A1 | COMPOSITIONS AND METHODS OF DECREASING MEDICATION ERRORS | AZHC, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| WO-2018195149-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES AND METHODS OF USE | Neonc Technologies, Inc. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20170297985-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | NEONC TECH INC (US) | 2017-10-19 | — | — | US | disclosed |
| EP-2898883-B1 | Pharmaceutical compositions comprising perillyl alcohol carbamates | NEONC TECHNOLOGIES INC (US) | 2016-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167669-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, CHAT, REL | PTGES 199/4885PTGS2 754/4885PTGS1 787/4885 |
| US-11147809-B2 | Methods of treating neurofibromatosis with perillyl alcohol | PMP22, CHAT, REL | PTGES 199/4885PTGS2 754/4885PTGS1 787/4885 |
| US-20170297985-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, REL, CHAT | PTGES 280/4885PTGS2 878/4885PTGS1 901/4885 |
| US-20240016800-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, CHAT, REL | PTGES 199/4885PTGS2 754/4885PTGS1 787/4885 |
| US-11786521-B2 | Methods of treating neurofibromatosis with perillyl alcohol | PMP22, CHAT, REL | PTGES 199/4885PTGS2 754/4885PTGS1 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.